Ten63 Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series A

  • Investors
  • 20

Ten63 Therapeutics General Information

Description

Developer of novel antineoplastic therapeutics designed to create remedial medicines to targets previously believed undruggable. The company's therapeutics are created using algorithms to build proprietary scaffold redesign and hopping technology, combining MOA and chemical design to achieve a more durable response, enabling drug researchers to screen trillions of molecules for resistance prediction and antibody redesign.

Contact Information

Website
www.ten63tx.com
Formerly Known As
Gavilán Biodesign
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 701 W Main Street
  • 5th Floor, Office 05-101
  • Durham, NC 27701
  • United States
+1 (984)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 701 W Main Street
  • 5th Floor, Office 05-101
  • Durham, NC 27701
  • United States
+1 (984)

Ten63 Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ten63 Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 19-Feb-2026 Completed Generating Revenue
5. Later Stage VC (Series A) 10-Jan-2025 Completed Generating Revenue
4. Later Stage VC (Series A) 08-Apr-2024 Completed Pre-Clinical Trials
3. Seed Round 27-Jan-2021 Completed Pre-Clinical Trials
2. Seed Round 03-Feb-2020 $3M $3.25M Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2019 $250K $250K Completed Pre-Clinical Trials
To view Ten63 Therapeutics’s complete valuation and funding history, request access »

Ten63 Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed-4
Seed-3
Seed-2 97,089 $0.000100 $2.57 $2.57 1x $2.57 2.26%
Seed-1 472,877 $0.000100 $5.87 $5.87 1x $5.87 11.03%
To view Ten63 Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Ten63 Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel antineoplastic therapeutics designed to create remedial medicines to targets previously believed undr
Drug Discovery
Durham, NC
29 As of 2026

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ten63 Therapeutics Competitors (83)

One of Ten63 Therapeutics’s 83 competitors is Relay Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Relay Therapeutics Formerly VC-backed Cambridge, MA
Exo Therapeutics Venture Capital-Backed Cambridge, MA
InterAx Venture Capital-Backed Schlieren, Switzerland
Vividion Therapeutics Formerly VC-backed San Diego, CA
Eureka Therapeutics Venture Capital-Backed Emeryville, CA
You’re viewing 5 of 83 competitors. Get the full list »

Ten63 Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ten63 Therapeutics Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
Black Opal Ventures Venture Capital Minority
Cape Fear BioCapital Venture Capital Minority
Chugai Venture Fund Corporate Venture Capital Minority
Gates Foundation Not-For-Profit Venture Capital Minority
Panorama (Tel Aviv) Venture Capital Minority
You’re viewing 5 of 20 investors. Get the full list »

Ten63 Therapeutics FAQs

  • When was Ten63 Therapeutics founded?

    Ten63 Therapeutics was founded in 2018.

  • Where is Ten63 Therapeutics headquartered?

    Ten63 Therapeutics is headquartered in Durham, NC.

  • What is the size of Ten63 Therapeutics?

    Ten63 Therapeutics has 29 total employees.

  • What industry is Ten63 Therapeutics in?

    Ten63 Therapeutics’s primary industry is Drug Discovery.

  • Is Ten63 Therapeutics a private or public company?

    Ten63 Therapeutics is a Private company.

  • What is Ten63 Therapeutics’s current revenue?

    The current revenue for Ten63 Therapeutics is .

  • How much funding has Ten63 Therapeutics raised over time?

    Ten63 Therapeutics has raised $50.5M.

  • Who are Ten63 Therapeutics’s investors?

    Black Opal Ventures, Cape Fear BioCapital, Chugai Venture Fund, Gates Foundation, and Panorama (Tel Aviv) are 5 of 20 investors who have invested in Ten63 Therapeutics.

  • Who are Ten63 Therapeutics’s competitors?

    Relay Therapeutics, Exo Therapeutics, InterAx, Vividion Therapeutics, and Eureka Therapeutics are some of the 83 competitors of Ten63 Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process